Literature DB >> 28266520

Targeted therapies: Reversal of fortunes for TKI resistance.

Louise Stone.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28266520     DOI： 10.1038/nrclinonc.2017.33

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.

Authors:  Rahul Aggarwal; Scott Thomas; Nela Pawlowska; Imke Bartelink; Jennifer Grabowsky; Thierry Jahan; Amy Cripps; Armand Harb; Jim Leng; Anne Reinert; Ilaria Mastroserio; Thach-Giao Truong; Charles J Ryan; Pamela N Munster
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.